Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials

Annals of the Rheumatic Diseases

Volumn 73, Issue 5, 2014, Pages 838-844

  Strand, Vibeke ^a   Levy, Roger A ^b   Cervera, Ricard ^c   Petri, Michelle A ^d   Birch, Helen ^e   Freimuth, William W ^f   Zhong, Z John ^f   Clarke, Ann E ^g  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

^c HOSPITAL CLÍNIC   (Spain)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

^f GLAXOSMITHKLINE   (United States)

^g MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTINUCLEAR ANTIBODY; BELIMUMAB; DOUBLE STRANDED DNA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE;

ADULT; ARTICLE; DRUG DOSE COMPARISON; EQ 5D QUESTIONNAIRE; FEMALE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; SCORING SYSTEM; SHORT FORM 36; SLE RESPONDER INDEX; SYSTEMIC LUPUS ERYTHEMATOSUS;

AUTOIMMUNE DISEASES; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOANTIBODIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84897990442     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202865     Document Type: Article

References (30)

1. Campbell R, Cooper GS, Gilkeson GS. Two aspects of the clinical and humanistic burden of systemic lupus erythematosus mortality risk and quality of life early in the course of disease. Arthritis Rheum 2008;59:458-64. (Pubitemid 351563526)
2. Lau CS, Mak A. The socioeconomic burden of SLE. Nat Rev Rheumatol 2009;5:400-4.
3. McElhone K, Abbott J, Gray J, et al. Patient perspective of systemic lupus erythematosus in relation to health-related quality of life concepts: a qualitative study. Lupus 2010;19:1640-7.
4. Strand V, Petri M, Buyon J, et al. Systemic lupus erythematosus (SLE) impacts all domains of health-related quality of life (HRQOL): baseline results from 5 randomized controlled trials (RCTs). Arthritis Rheum 2006;54:S277.
5. Strand V, Petri M, Buyon J, et al. Systemic lupus erythematosus (SLE) impacts all domains of health-related quality of life (HRQOL): baseline results from five randomized controlled trials (RCTs). Lupus 2007;16:260.
6. Thumboo J, Strand V. Health-related quality of life in patients with systemic lupus erythematosus: an update. Ann Acad Med Singapore 2007;36:115-22. (Pubitemid 46640263)
7. Zonana-Nacach A, Roseman JM, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups. VI: factors associated with fatigue within 5 years of criteria diagnosis. Lupus 2000;9:101-9. (Pubitemid 30171106)
8. Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009;119:1066-73.
9. Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008;58:2453-9.
10. Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003;48:3253-65. (Pubitemid 37409340)
11. Furie R, Petri M, Zamani O, et al. BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.
12. Navarra SV, Guzmán RM, Gallacher AE, et al.; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized, placebo-controlled phase 3 trial. Lancet 2011;377:721-31.
13. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51.
14. Ware JE, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998;51:903-12. (Pubitemid 28527145)
15. Ware JE, Kosinski M, Dewey JE. How to core Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated, 2000.
16. Strand V, Chu AD. Measuring outcomes in systemic lupus erythematosus clinical trials. Expert Rev Pharmacoecon Outcomes Res 2011;11:455-68.
17. Strand V, Chu AD. Generic versus disease-specific measures of health-related quality of life in systemic lupus erythematosus. J Rheumatol 2011;38:1821-3.
18. Strand V, Crawford B. Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies. Expert Rev Pharmacoecon Outcomes Res 2005;5:317-26. (Pubitemid 40894969)
19. Strand V, Crawford B, Singh J, et al. Use of "spydergrams" to present and interpret health related quality of life data across rheumatic diseases. Ann Rheum Dis 2009;68:1800-4.
20. Strand V, Sharp V, Koenig AS, et al. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis 2012;71:1143-50.
21. Cella D, Yount S, Sorensen M, et al. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005;32:811-19. (Pubitemid 40676488)
22. Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health 2008;7:1131-43.
23. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states development and testing of the D1 valuation model. Med Care 2005;43:203-20. (Pubitemid 40353904)
24. Szende A, Oppe M, Devlin NJ EQ-5D value sets: inventory, comparative review and user guide. Series. EuroQol Group Monographs Volume 2. Dordrecht, The Netherlands: Springer, 2007.
25. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61:1168-78.
26. Manzi S, Sánchez-Guerrero J, Merrill JT, et al.; on behalf of the BLISS-52 and BLISS-76 Study Groups. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012;71:1833-8.
27. Stohl W, Hiepe F, Latinis KM, et al. BLISS-52 and BLISS-76 Study Groups. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012;64:2328-37.
28. van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012;71:1343-9.
29. Lupus Foundation of America, Inc. General Lupus Fact Sheet. http://www.lupus.org/ webmodules/webarticlesnet/templates/new-newsroomnews.aspx? articleid=351& zoneid=59 (accessed 20 Jul 2012).
30. Schneider M, Strand V, Nikai E, et al. An assessment of impairment of productivity among SLE patients. Ann Rheum Dis 2012;71:538